Bicycle Therapeutics plc
BCYC
$7.16
$0.020.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.20% | -51.28% | -38.18% | 30.76% | 48.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.20% | -51.28% | -38.18% | 30.76% | 48.60% |
| Cost of Revenue | -26.92% | -30.31% | -48.47% | -63.05% | 26.97% |
| Gross Profit | 30.75% | 26.57% | 55.24% | 85.45% | -22.03% |
| SG&A Expenses | 21.79% | 27.94% | 20.92% | 16.54% | 7.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.43% | 37.95% | 23.76% | 13.01% | 21.06% |
| Operating Income | -47.63% | -57.21% | -38.09% | -10.49% | -16.99% |
| Income Before Tax | -49.05% | -52.26% | -25.41% | 3.02% | -5.48% |
| Income Tax Expenses | 34.73% | -348.11% | -418.96% | -427.04% | -569.04% |
| Earnings from Continuing Operations | -50.75% | -46.56% | -20.85% | 6.44% | -2.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.75% | -46.56% | -20.85% | 6.44% | -2.93% |
| EBIT | -47.63% | -57.21% | -38.09% | -10.49% | -16.99% |
| EBITDA | -49.60% | -59.04% | -39.26% | -10.52% | -17.12% |
| EPS Basic | -10.30% | 7.95% | 29.70% | 43.93% | 34.10% |
| Normalized Basic EPS | -12.05% | 2.88% | 26.11% | 41.23% | 33.33% |
| EPS Diluted | -10.30% | 7.95% | 29.70% | 43.93% | 34.10% |
| Normalized Diluted EPS | -12.05% | 2.88% | 26.11% | 41.23% | 33.33% |
| Average Basic Shares Outstanding | 34.40% | 56.61% | 67.52% | 63.58% | 59.07% |
| Average Diluted Shares Outstanding | 34.40% | 56.61% | 67.52% | 63.58% | 59.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |